Functional MRI (fMRI) Studies
Functional Magnetic Resonance Imaging (fMRI) is a class of imaging methods developed in metabolism to demonstrate regional, time-varying changes in the brain. fMRI has been used in an exceptionally large number of studies in cognitive neurosciences, clinical psychiatry/psychology, and presurgical planning. The popularity of fMRI derives from its widespread availability, non-invasive nature, relatively low cost, and good spatial resolution. Increasingly, fMRI is being used as a biomarker for disease to monitor therapy, or for studying pharmacological efficacy.
Fig.1 Typical fMRI workflow. (Soares, 2016)
Analysis Methods of fMRI
The most employed method in the analysis of task-based fMRI is Statistical Parametric Mapping (SPM), which is based on the GLM. GLM’s popularity is based on its straightforward implementation, interpretability, and computability.
The first method applied to rs-fMRI was seed-based correlation analysis.
Fig.2 Commonly used analysis methods in functional MRI studies. (Soares, 2016)
Strengths and Weaknesses of fMRI
A primary strength of fMRI is its relatively high spatial resolution and availability. In addition, it is readily available to both clinical and academic researchers, is noninvasive, and can provide high-resolution anatomic scans for localization, vessel identification, or development of maps of white matter connectivity through the use of diffusion tensor imaging (DTI).
Because BOLD contrast derives from the sluggish hemodynamic response to metabolic changes, a significant weakness is its low temporal resolution. Other weaknesses include the scanner’s loud noise associated with switched magnetic fields, which can cause confounds in studies of audition networks and resting states.
Clinical Applications of fMRI
Current clinical methods for language lateralisation are highly invasive. fMRI offers a promising alternative approach. fMRI also provides more specific anatomical information.
fMRI is an attractive strategy for this functional mapping because of its potentially wide availability in clinical centers and relatively low cost.
With simultaneous EEG and fMRI, it has been possible to identify ictal foci in patients with subclinical seizures.
fMRI studies are showing that functional reorganisation is a general response to brain injury. fMRI studies of learning in healthy subjects show that changes in functional brain organisation also may be induced.
fMRI can be sensitive to the early stages of brain pathology. A pioneering illustration of this approach was an fMRI based memory study of a group of apparently healthy subjects at risk of developing earlier onset Alzheimer’s disease. One year after fMRI scanning, those who were beginning to develop memory problems in the early clinical expression of presumed Alzheimer’s disease were identified.
Using fMRI to guide therapeutic development is one of the most exciting prospects for the technique. Initial work has not just been for drug development and response monitoring. The greatest impact may be on areas in which sensitive and objective endpoints were previously difficult to define, for example, neurorehabilitation.
Recent evidence suggests that functional neuroimaging methods, such as fMRI, may be relatively sensitive to brain changes at the system level, suggesting that this approach may also provide a powerful strategy for identifying specific genetic factors that may play a dominant role in cognitive processes. Creative Biolabs has a very strong technical force in the field of neuroscience research, focusing on fMRI research in recent years. We can develop customized fMRI methods for customer’s neuroscience research projects to make the greatest breakthrough in your project. Contact us for more information.
Reference
- Soares, J.M.; et al. A Hitchhiker's Guide to Functional Magnetic Resonance Imaging. Front Neurosci. 2016 Nov 10;10:515.
- iNeuMab™ Anti-GARP Antibody (NRP-0422-P1639) (Cat#: NRP-0422-P1639)
- iNeuMab™ Anti-ApoC3 BBB Shuttle Antibody (NRZP-1022-ZP3503) (Cat#: NRZP-1022-ZP3503)
- iNeuMab™ Anti-Alpha Synuclein BBB Shuttle Antibody (NRZP-1022-ZP4050) (Cat#: NRZP-1022-ZP4050)
- iNeuMab™ Anti-SEZ6 Antibody (NRP-0422-P515) (Cat#: NRP-0422-P515)
- iNeuMab™ Anti-pTau Antibody (NRP-0422-P1719) (Cat#: NRP-0422-P1719)
- iNeuMab™ Anti-Alpha Synuclein Antibody (NRP-0422-P614) (Cat#: NRP-0422-P614)
- iNeuMab™ Anti-TREM2 Antibody (NRP-0422-P792) (Cat#: NRP-0422-P792)
- iNeuMab™ Anti-Amyloid Beta 1-15 Antibody (NRP-0422-P867) (Cat#: NRP-0422-P867)
- iNeuMab™ Anti-GD2 Antibody (NRZP-1222-ZP767) (Cat#: NRZP-1222-ZP767)
- iNeuMab™ Anti-TREM2 BBB Shuttle Antibody (NRZP-1022-ZP4114) (Cat#: NRZP-1022-ZP4114)
- Human Brain Astroblastoma U-87 MG (Cat#: NCL2110P117)
- Human Astrocytes (Cat#: NCC20-9PZ01)
- Mouse Microglia N9 (Cat#: NCL2110P073)
- Rat Muller Cell (Cat#: NCL2110P040)
- Mouse Midbrain Dopaminergic Neuron Cell MN9D (Cat#: NCL2110P059)
- Mouse Glioma Cell Line GL261-GFP (Cat#: NCL-2108P04)
- iNeu™ Human Sensory Neurons (Cat#: NCL-2103-P62)
- Mouse Retinal Ganglion Cell Line RGC-5 (Cat#: NCL2110P154)
- Rat Olfactory Ensheathing Cells (Cat#: NRZP-1122-ZP162)
- Rat Retinal Muller Cell Line, Immortalized (Cat#: NCL-21P6-192)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- AAV2/9-hEF1a-fDIO-eNpHR 3.0-mCherry-WPRE-pA (Cat#: NTA-2012-ZP78)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- Dextran, NHS Activated (Cat#: NRZP-0722-ZP124)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
- Human apolipoprotein E (APOE) (NM_000041) ORF clone, Untagged (Cat#: NEP-0421-R0232)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- Tau Antisense Oligonucleotide (IONIS-MAPTRx) (Cat#: NV-2106-P29)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- Rat Parkinson disease (autosomal recessive, juvenile) 2, parkin (Park2) (NM_020093) ORF clone/lentiviral particle, Myc-DDK Tagged (Cat#: NEP-0621-R0041)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
- App Rat amyloid beta (A4) precursor protein (App)(NM_019288) ORF clone, Untagged (Cat#: NEP-0421-R0053)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroPro™ Anti-EPO BBB Shuttle Protein (Cat#: NRZP-0423-ZP508)
- NeuroPro™ Anti-ASA BBB Shuttle Protein (Cat#: NRZP-0423-ZP504)
- NeuroPro™ Anti-NAGLU BBB Shuttle Protein (Cat#: NRZP-0423-ZP506)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP498)
- NeuroPro™ Anti-IDS BBB Shuttle Protein (Cat#: NRZP-0423-ZP503)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP509)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP501)